• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Inclusion Body Myositis: Update on Pathogenesis and Treatment.包涵体肌炎:发病机制和治疗的最新进展。
Neurotherapeutics. 2018 Oct;15(4):995-1005. doi: 10.1007/s13311-018-0658-8.
2
[The etiology and pathogenesis of sporadic inclusion body myositis].[散发性包涵体肌炎的病因及发病机制]
Brain Nerve. 2014 Nov;66(11):1385-94. doi: 10.11477/mf.1416200044.
3
Inclusion body myositis and sarcoid myopathy: coincidental occurrence or associated diseases.包涵体肌炎与结节病性肌病:偶发还是相关疾病?
Neuromuscul Disord. 2015 Apr;25(4):297-300. doi: 10.1016/j.nmd.2014.12.005. Epub 2014 Dec 19.
4
Myopathies featuring non-caseating granulomas: Sarcoidosis, inclusion body myositis and an unfolding overlap.伴有非干酪样肉芽肿的肌病:结节病、包涵体肌炎和不断出现的重叠。
Neuromuscul Disord. 2019 Jan;29(1):39-47. doi: 10.1016/j.nmd.2018.10.007. Epub 2018 Nov 9.
5
Sporadic inclusion body myositis: an unsolved mystery.散发性包涵体肌炎:一个未解之谜。
Acta Reumatol Port. 2009 Apr-Jun;34(2A):161-82.
6
Inclusion body myositis.包涵体肌炎。
Neurol Clin. 2014 Aug;32(3):629-46, vii. doi: 10.1016/j.ncl.2014.04.001. Epub 2014 Jun 6.
7
Inclusion body myositis.包涵体肌炎。
Semin Neurol. 2012 Jul;32(3):237-45. doi: 10.1055/s-0032-1329197. Epub 2012 Nov 1.
8
Inclusion body myositis.包涵体肌炎。
Curr Neurol Neurosci Rep. 2013 Jan;13(1):321. doi: 10.1007/s11910-012-0321-4.
9
Congenital myopathy with abundant ring fibres, rimmed vacuoles and inclusion body myositis-type inclusions.伴有大量环状纤维、镶边空泡及包涵体肌炎样包涵体的先天性肌病。
Neuropediatrics. 2003 Feb;34(1):40-4. doi: 10.1055/s-2003-38616.
10
Update on Inclusion Body Myositis.包涵体肌炎的最新进展。
Curr Rheumatol Rep. 2018 Jun 28;20(8):52. doi: 10.1007/s11926-018-0755-z.

引用本文的文献

1
Ageing Signatures and Disturbed Muscle Regeneration in Muscle Proteome of Inclusion Body Myositis.包涵体肌炎肌肉蛋白质组中的衰老特征与肌肉再生紊乱
J Cachexia Sarcopenia Muscle. 2025 Jun;16(3):e13845. doi: 10.1002/jcsm.13845.
2
Inclusion Body Myositis: A Case Report.包涵体肌炎:病例报告
Cureus. 2025 Apr 1;17(4):e81581. doi: 10.7759/cureus.81581. eCollection 2025 Apr.
3
Treatment guidelines for idiopathic inflammatory myopathies in adults: a comparative review.成人特发性炎性肌病的治疗指南:一项比较性综述。
Rheumatology (Oxford). 2025 Jun 1;64(6):3288-3302. doi: 10.1093/rheumatology/keaf116.
4
Association of HLA-DR, HLA-DQ, and HLA-B alleles with inclusion body myositis risk: A systematic review, a meta-analysis, a meta-regression and a trial sequential analysis.HLA-DR、HLA-DQ和HLA-B等位基因与包涵体肌炎风险的关联:一项系统评价、荟萃分析、荟萃回归及试验序贯分析
Int J Immunopathol Pharmacol. 2025 Jan-Dec;39:3946320251321747. doi: 10.1177/03946320251321747.
5
Efficacy and safety of pharmacological treatments in inclusion body myositis: a systematic review.药物治疗包涵体肌炎的疗效与安全性:一项系统评价
RMD Open. 2025 Jan 22;11(1):e005176. doi: 10.1136/rmdopen-2024-005176.
6
Effect of sirolimus on muscle in inclusion body myositis observed with magnetic resonance imaging and spectroscopy.西罗莫司对包涵体肌炎肌肉的磁共振成像和波谱观察的影响。
J Cachexia Sarcopenia Muscle. 2024 Jun;15(3):1108-1120. doi: 10.1002/jcsm.13451. Epub 2024 Apr 13.
7
Effects of sporadic inclusion body myositis on skeletal muscle fibre type specific morphology and markers of regeneration and inflammation.散发性包涵体肌炎对骨骼肌纤维类型特异性形态及再生和炎症标志物的影响。
Rheumatol Int. 2024 Jun;44(6):1077-1087. doi: 10.1007/s00296-024-05567-8. Epub 2024 Apr 6.
8
Cytotoxic immune cells do not affect TDP-43 and p62 sarcoplasmic aggregation but influence TDP-43 localisation.细胞毒性免疫细胞不会影响 TDP-43 和 p62 肌浆聚集,但会影响 TDP-43 的定位。
Sci Rep. 2023 Sep 23;13(1):15935. doi: 10.1038/s41598-023-42824-5.
9
Face to Face: deciphering facial involvement in inclusion body myositis.直面肌病:包涵体肌炎的面肌受累解读
J Neurol. 2024 Jan;271(1):410-418. doi: 10.1007/s00415-023-11986-7. Epub 2023 Sep 23.
10
Influence of Inflammatory Cytokines IL-1 and IFN on Sarcoplasmic Aggregation of p62 and TDP-43 in Myotubes.炎症细胞因子 IL-1 和 IFN 对肌管中 p62 和 TDP-43 肌浆聚集的影响。
Mediators Inflamm. 2023 Sep 12;2023:9018470. doi: 10.1155/2023/9018470. eCollection 2023.

本文引用的文献

1
Endoplasmic Reticulum Stress Induces Myostatin High Molecular Weight Aggregates and Impairs Mature Myostatin Secretion.内质网应激诱导肌肉生长抑制素高分子量聚集体形成并损害成熟肌肉生长抑制素分泌。
Mol Neurobiol. 2018 Nov;55(11):8355-8373. doi: 10.1007/s12035-018-0997-9. Epub 2018 Mar 15.
2
Rapamycin for inclusion body myositis: targeting non-inflammatory mechanisms.雷帕霉素用于治疗包涵体肌炎:针对非炎症机制
Rheumatology (Oxford). 2019 Mar 1;58(3):375-376. doi: 10.1093/rheumatology/key043.
3
Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive ALS.随机、双盲、安慰剂对照试验中使用盐酸氨氯地平治疗快速进展性肌萎缩侧索硬化症。
Neurology. 2018 Feb 13;90(7):e565-e574. doi: 10.1212/WNL.0000000000004960. Epub 2018 Jan 24.
4
Unfounded Claims of Improved Functional Outcomes Attributed to Follistatin Gene Therapy in Inclusion Body Myositis.关于卵泡抑素基因疗法可改善包涵体肌炎功能结局的毫无根据的说法。
Mol Ther. 2017 Oct 4;25(10):2235-2237. doi: 10.1016/j.ymthe.2017.09.002. Epub 2017 Sep 8.
5
Botulinum toxin alleviates dysphagia of patients with inclusion body myositis.肉毒毒素可缓解包涵体肌炎患者的吞咽困难。
J Neurol Sci. 2017 Sep 15;380:142-147. doi: 10.1016/j.jns.2017.07.031. Epub 2017 Jul 24.
6
A Systematic Review and Meta-Analysis of Prevalence Studies of Sporadic Inclusion Body Myositis.一项关于散发性包涵体肌炎患病率研究的系统评价和荟萃分析。
J Neuromuscul Dis. 2017;4(2):127-137. doi: 10.3233/JND-160198.
7
Burden of illness and healthcare resource use in United States patients with sporadic inclusion body myositis.美国散发性包涵体肌炎患者的疾病负担和医疗资源利用情况
Muscle Nerve. 2017 Nov;56(5):861-867. doi: 10.1002/mus.25686. Epub 2017 May 30.
8
Pathomechanisms of anti-cytosolic 5'-nucleotidase 1A autoantibodies in sporadic inclusion body myositis.特发性包涵体肌炎中抗胞质 5'-核苷酸酶 1A 自身抗体的致病机制。
Ann Neurol. 2017 Apr;81(4):512-525. doi: 10.1002/ana.24919. Epub 2017 Apr 3.
9
Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes.卵泡抑素基因疗法治疗散发性包涵体肌炎可改善功能预后。
Mol Ther. 2017 Apr 5;25(4):870-879. doi: 10.1016/j.ymthe.2017.02.015. Epub 2017 Mar 6.
10
The role of p62/SQSTM1 in sporadic inclusion body myositis.p62/SQSTM1在散发性包涵体肌炎中的作用。
Neuromuscul Disord. 2017 Apr;27(4):363-369. doi: 10.1016/j.nmd.2016.12.009. Epub 2016 Dec 29.

包涵体肌炎:发病机制和治疗的最新进展。

Inclusion Body Myositis: Update on Pathogenesis and Treatment.

机构信息

Neuromuscular Medicine Division, Department of Neurology, Mayo Clinic, Rochester, Minnesota, 55905, USA.

Neuromuscular Medicine Division, Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, 66103, USA.

出版信息

Neurotherapeutics. 2018 Oct;15(4):995-1005. doi: 10.1007/s13311-018-0658-8.

DOI:10.1007/s13311-018-0658-8
PMID:30136253
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6277289/
Abstract

Inclusion body myositis is the most common acquired myopathy after the age of 50. It is characterized by progressive asymmetric weakness predominantly affecting the quadriceps and/or finger flexors. Loss of ambulation and dysphagia are major complications of the disease. Inclusion body myositis can be associated with cytosolic 5'-nucleotidase 1A antibodies. Muscle biopsy usually shows inflammatory cells surrounding and invading non-necrotic muscle fibers, rimmed vacuoles, congophilic inclusions, and protein aggregates. Disease pathogenesis remains poorly understood and consists of an interplay between inflammatory and degenerative pathways. Antigen-driven, clonally restricted, cytotoxic T cells represent a main feature of the inflammatory component, whereas abnormal protein homeostasis with protein misfolding, aggregation, and dysfunctional protein disposal is the hallmark of the degenerative component. Inclusion body myositis remains refractory to treatment. Better understanding of the disease pathogenesis led to the identification of novel therapeutic targets, addressing both the inflammatory and degenerative pathways.

摘要

包涵体肌炎是 50 岁以后最常见的获得性肌病。其特征是进行性非对称性无力,主要影响股四头肌和/或手指屈肌。丧失活动能力和吞咽困难是该病的主要并发症。包涵体肌炎可与胞质 5'-核苷酸酶 1A 抗体相关。肌肉活检通常显示炎性细胞围绕和侵入非坏死的肌纤维,边缘空泡,亲刚果红包涵体和蛋白聚集物。疾病发病机制仍不清楚,由炎症和退行性途径的相互作用组成。抗原驱动的、克隆受限的细胞毒性 T 细胞是炎症成分的主要特征,而异常的蛋白质动态平衡伴蛋白质错误折叠、聚集和功能失调的蛋白质处理则是退行性成分的标志。包涵体肌炎对治疗仍有抗性。对疾病发病机制的更好理解导致了新的治疗靶点的确定,既针对炎症途径又针对退行性途径。